Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics CoSHSE:603658 +0.33%95 PS Ratio is 4.57 as of Aug. 27, 2026, which is 53% below its 10-year median of 9.82. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Autobio Diagnostics Co ranks worse than 66.67% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Autobio Diagnostics Co's share price is ¥33.52.
Autobio Diagnostics Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥7.33. Hence, Autobio Diagnostics Co's PS Ratio for today is 4.57.
The historical rank and industry rank for Autobio Diagnostics Co's PS Ratio or its related term are showing as below:
SHSE:603658'
s PS Ratio Range Over the Past 10 Years
Min: 3.88 Med: 9.82 Max: 28.63
Current: 4.57
During the past 13 years, Autobio Diagnostics Co's highest PS Ratio was 28.63. The lowest was 3.88. And the median was 9.82.
SHSE:603658's PS Ratio is ranked worse than 66.67% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.995
vs SHSE:603658: 4.57
Autobio Diagnostics Co Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Autobio Diagnostics Co was -3.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.60% per year.
During the past 13 years, Autobio Diagnostics Co's highest 3-Year average Revenue per Share Growth Rate was 36.70% per year. The lowest was -0.90% per year. And the median was 27.80% per year.
Autobio Diagnostics Co (SHSE:603658) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Autobio Diagnostics Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Autobio Diagnostics Co's Share Price of today is ¥33.52. Autobio Diagnostics Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥7.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Autobio Diagnostics Co (SHSE:603658) has a PS Ratio of 4.57 as of Aug. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Autobio Diagnostics Co and its competitors. This is 53% below median its historical median of 9.82. Over the past decade, Autobio Diagnostics Co's PS Ratio has ranged from 3.88 to 28.63. According to the industry distribution chart, Autobio Diagnostics Co ranks #536 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 66.7%.
Is Autobio Diagnostics Co's PS Ratio too high?
Autobio Diagnostics Co's current PS Ratio of 4.57 is 53% below median its 10-year median of 9.82. Over the past 10 years, this metric has ranged from a low of 3.88 to a high of 28.63. The Medical Devices & Instruments industry median PS Ratio is 3.00. Autobio Diagnostics Co's value of 4.57 is 52.6% above this industry median. Based on the distribution chart, Autobio Diagnostics Co ranks #536 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #536 out of 804 companies for PS Ratio. This places Autobio Diagnostics Co in the lower half of its industry. The industry median PS Ratio is 3.00. Autobio Diagnostics Co's value of 4.57 is 52.6% above this benchmark. Historically, Autobio Diagnostics Co's own PS Ratio has ranged from 3.88 to 28.63 over the past decade. While the company's 10-year median is 9.82 vs. the industry median of 3.00, Autobio Diagnostics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 3.00, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autobio Diagnostics Co's current PS Ratio of 4.57 is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current PS Ratio is 4.57, which is 53% below median its own 10-year median of 9.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.31, compared to a current price of ¥33.52 — trading 16.8% below its estimated fair value. The current PS Ratio is 4.57, which is 53% below median its 10-year median of 9.82 and 52.6% above the Medical Devices & Instruments industry median of 3.00. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current PS Ratio is 4.57 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥33.52 is trading 16.8% below its estimated GF Value™ of ¥40.31.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
PS Ratio: 4.57 (53% below median its 10-year median of 9.82)
GF Value™: ¥40.31 vs. price of ¥33.52 (16.8% below fair value)
Industry Position: 52.6% above the Medical Devices & Instruments median (#536 of 804)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
